Stada widens biotech drug offering with filgrastim license

FRANKFURT (Reuters) - Germany's Stada will sell a version of U.S. drugmaker Amgen's blockbuster cancer treatment filgrastim in Europe, keeping faith with the difficult market for copies of medicines developed using biotechnology.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news